References

Unresolved reference

2025 · External reference

Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma control (LIASON) study

10.1186/s12931-016-0374-z · 2016 · External reference

Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma

2020 · External reference

Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study

10.1136/thorax-2021-217032 · 2023 · External reference

Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline

10.1183/13993003.00588-2019 · 2020 · External reference

Unresolved reference

2020 · External reference

Unresolved reference

2024 · External reference

Unresolved reference

2024 · External reference

Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial

10.1016/s2213-2600(20)30389-1 · 2021 · External reference

International variation in severe exacerbation rates in patients with severe asthma

10.1016/j.chest.2024.02.029 · 2024 · External reference

The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA

10.1186/s12890-017-0409-3 · 2017 · External reference

Association between pulmonary function and asthma symptoms

10.1016/j.jaip.2019.04.019 · 2019 · External reference

Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY

10.1177/17534666241254212 · 2024 · External reference

Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability

10.1016/s0149-2918(02)85133-5 · 2002 · External reference

Measuring respiratory symptoms in moderate/severe asthma: evaluation of a respiratory symptom tool, the E-RS®: COPD in asthma populations

10.1186/s41687-021-00338-6 · 2021 · External reference

Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials

10.1186/s12931-014-0124-z · 2014 · External reference

Reliability, validity and responsiveness of E-RS:COPD in patients with spirometric asthma-COPD overlap

10.1186/s12931-019-1070-6 · 2019 · External reference

Development and validation of a questionnaire to measure asthma control

10.1034/j.1399-3003.1999.14d29.x · 1999 · External reference

Unresolved reference

2017 · External reference

Executive summary: Japanese guidelines for adult asthma (JGL) 2021

10.1016/j.alit.2023.02.006 · 2023 · External reference

Association of dose of inhaled corticosteroids and frequency of adverse events

10.1164/rccm.202402-0368oc · 2025 · External reference

Association of stepping up to high-dose inhaled corticosteroids and risk of future asthma exacerbations: data from the United States

10.1016/j.jaip.2025.10.005 · 2026 · External reference

Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies

10.1183/13993003.04233-2020 · 2021 · External reference

Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: a systematic review and meta-analysis

10.1001/jama.2021.7872 · 2021 · External reference

Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment

10.1016/j.anai.2023.08.609 · 2023 · External reference

An expert consensus framework for asthma remission as a treatment goal

10.1016/j.jaci.2019.12.006 · 2020 · External reference

The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study

10.1016/s2213-2600(21)00004-7 · 2021 · External reference

Analysis of airway inflammation demonstrates a mechanism for T2-biologic failure in asthma

10.1016/j.jaci.2025.05.031 · 2025 · External reference

Role and impact of chronic cough in individuals with asthma from the general population

10.1016/j.jaip.2019.02.021 · 2019 · External reference

Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma

10.1016/j.jaip.2018.01.016 · 2018 · External reference

Tiotropium for refractory cough in asthma via cough reflex sensitivity: a randomized, parallel, open-label trial

10.1016/j.anai.2023.03.032 · 2023 · External reference

The efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study

10.1080/02770903.2025.2455416 · 2025 · External reference

Effect of bronchoconstriction on airway remodeling in asthma

10.1056/nejmoa1014350 · 2011 · External reference

Tiotropium attenuates IL-13-induced goblet cell metaplasia of human airway epithelial cells

10.1136/thoraxjnl-2014-205731 · 2015 · External reference

The mode of action of anticholinergics in asthma

10.1183/13993003.01247-2017 · 2018 · External reference

The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review

10.1183/16000617.0196-2021 · 2022 · External reference

Corticosteroid and long-acting ß-agonist therapy reduces epithelial goblet cell metaplasia

10.1111/cea.13015 · 2017 · External reference

A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial

10.1016/s0091-6749(06)80008-4 · 1992 · External reference

Acquired cilia dysfunction in chronic rhinosinusitis

10.2500/ajra.2012.26.3716 · 2012 · External reference

Gastroesophageal reflux disease is a risk factor for sputum production in the general population: the Nagahama study

10.1186/s12931-020-01601-y · 2021 · External reference

Bronchiectasis

10.1038/s41572-018-0042-3 · 2018 · External reference

Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma

10.3109/02770903.2014.975358 · 2015 · External reference

Effects of inhaled corticosteroids on cough threshold in patients with bronchial asthma

10.1006/pupt.2000.0264 · 2001 · External reference

Managing chronic cough due to asthma and NAEB in adults and adolescents: CHEST guideline and expert panel report

10.1016/j.chest.2019.12.021 · 2020 · External reference

Real-world evidence: patient views on asthma in respiratory specialist clinics in America

10.1016/j.anai.2020.12.015 · 2021 · External reference

Long-term use of short-acting beta(2)-agonists in patients with adult-onset asthma

10.1016/j.jaip.2022.03.027 · 2022 · External reference

Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review

2020 · External reference

Effect of stepping up to high-dose inhaled corticosteroids in patients with asthma: UK database study

10.1016/j.jaip.2022.10.040 · 2023 · External reference

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

10.1016/s0140-6736(16)31324-1 · 2016 · External reference

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

10.1016/j.jaci.2013.05.020 · 2013 · External reference

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials

10.1016/s2213-2600(15)00042-9 · 2015 · External reference

Mepolizumab treatment in patients with severe eosinophilic asthma

10.1056/nejmoa1403290 · 2014 · External reference

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

10.1056/nejmoa0805435 · 2009 · External reference

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

10.1016/s2213-2600(17)30344-2 · 2018 · External reference

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

10.1016/s2213-2600(16)30031-5 · 2016 · External reference

Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists

10.1016/j.jaci.2006.01.011 · 2006 · External reference